In the originally published article there was an error in the abbreviations for Figure 1. The abbreviation “MEP” was incorrectly defined as “monoethyl phospohate”; this should read “megakaryocytic erythroid progenitor”.
Share this Article
Related Content In Immunotherapy
New Checkpoint Inhibitors and Immunotherapies for Solid Tumours
touchREVIEWS in Oncology & Haematology. 2021;17(2):90–4
The antitumor activity of immune checkpoint inhibotors in various solid and haematologic malignancies has substantially increased immunotherapy implications for cancer. Once only a niche treatment for selected cancers (renal cancer and melanoma), now cancer immunotherapy has become an important option for many patients, even moving into the first-line systemic treatment setting for melanoma, non-small cell […]
Emerging Targeted and Immunotherapies in Cholangiocarcinoma
Oncology & Hematology Review (US). 2019;15(2):71–5
Cholangiocarcinoma is an epithelial malignancy of the biliary system characterized by cholangiocyte differentiation, and its incidence is on the rise. Currently, cholangiocarcinomas are classified by their anatomical location in the biliary system as intrahepatic cholangiocarcinoma, distal cholangiocarcinoma, or hilar cholangiocarcinoma. Since 2010, the standard of care in all advanced, inoperable biliary tract cancers has been combination […]
PARP Inhibitors may be Beneficial in a Broader Range of Patients
Oncology & Hematology Review (US). 2019;15(2):66–7
Q. What is the role of PARP-1 in the pathogenesis of cancer? PARP-1 is a protein that resides in the cell nucleus where it plays a role in most, if not all, nuclear functions (e.g. DNA repair, transcription, RNA processing, RNA ribosomal transcription). PARP-1 uses these pathways to assist the cancer cell in its uncontrolled […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!